<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Teduglutide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Teduglutide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Teduglutide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="88324" href="/d/html/88324.html" rel="external">see "Teduglutide: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="122063" href="/d/html/122063.html" rel="external">see "Teduglutide: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16116959"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gattex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871544"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Revestive</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15846420"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Glucagon-Like Peptide-2 (GLP-2) Analog</li></ul></div>
<div class="block doa drugH1Div" id="F16136127"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6dd4d4b1-8669-40db-b88c-a3fd020ce8a6">Short bowel syndrome, parenteral support dependent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Short bowel syndrome, parenteral support dependent:</b>
<b>SUBQ:</b> 0.05 mg/kg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed, take as soon as possible on that day; do <b>NOT</b> take 2 doses on the same day.</p></div>
<div class="block dora drugH1Div" id="F50991749"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: <b>SUBQ:</b> Reduce dose to 0.025 mg/kg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD: <b>SUBQ: </b>Reduce dose to 0.025 mg/kg once daily.</p></div>
<div class="block doha drugH1Div" id="F50988843"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F16136128"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F53471550"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="122063" href="/d/html/122063.html" rel="external">see "Teduglutide: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c631147f-b087-400f-a91a-bd50f41aa233">Short bowel syndrome, requiring parenteral support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Short bowel syndrome, requiring parenteral support: </b>Children and Adolescents weighing ≥10 kg: SubQ: 0.05 mg/kg/dose once daily; reductions in parenteral nutrition requirements (including calorie and volume) and advancement of enteral nutrition were observed as early as week 4 of teduglutide therapy in an open-label trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27855998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27855998'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F53471551"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: SubQ:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>: Reduce dose to 0.025 mg/kg/dose once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: Reduce dose to 0.025 mg/kg/dose once daily.</p></div>
<div class="block dohp drugH1Div" id="F53471552"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F16136026"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Fluid retention (1% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (30%), nausea (23%), abdominal distension (20%), vomiting (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (3% to 54%; incidence increased with prolonged use)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Intestinal stoma complication (42%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (10%), cardiac failure (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Sleep disturbance (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal hemorrhage (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Flatulence (9%), decreased appetite (7%), intestinal stenosis (&lt;5%; including colonic), pancreatic disease (&lt;5%; duct stenosis), cholecystitis (4%), intestinal obstruction (≤4%), gallbladder perforation (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (5%), dyspnea (&lt;5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema, flushing, jugular vein distention</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, pruritus, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholelithiasis, cholestasis, colonic polyp, pancreatic pseudocyst, pancreatitis, rectal polyp</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematoma</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eyelid edema</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Cholangitis, malignant neoplasm</p></div>
<div class="block coi drugH1Div" id="F16136004"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to teduglutide or any component of the formulation; active gastrointestinal (GI) malignancy (GI tract, hepatobiliary, pancreatic); history of GI tract malignancies (including the hepatobiliary system and pancreas) within the last 5 years.</p></div>
<div class="block war drugH1Div" id="F16136005"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Colorectal polyps: Short bowel syndrome: Development of colorectal polyps has occurred. In adults, perform a baseline colonoscopy of the entire colon with polyp removal ≤6 months prior to initiation of therapy. Follow-up colonoscopy (or alternative imaging) should be performed at 1 year and at least every 5 years thereafter, or more frequent if clinically indicated. In children and adolescents, perform fecal occult blood testing at baseline (prior to therapy) and annually; if unexplained blood detected, perform colonoscopy/sigmoidoscopy. Additionally, perform colonoscopy/sigmoidoscopy after 1 year, every 5 years thereafter during therapy, or for new or unexplained GI bleeding. Discontinue teduglutide in patients who develop colorectal cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Increased fluid absorption and subsequent fluid overload/congestive heart failure has been reported; consider modification of parenteral support in patients who develop fluid overload, especially in patients with underlying cardiovascular disease. If significant cardiac deterioration develops, reassess the need for continued teduglutide treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder/biliary tract disease: Cholecystitis, cholangitis, and cholelithiasis have been reported; monitor serum bilirubin and alkaline phosphatase ≤6 month prior to initiation of therapy and at least every 6 months for duration of therapy. If clinically meaningful changes are detected, perform further evaluation including gallbladder/biliary tract imaging and reassess the need for continued teduglutide treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intestinal obstruction: Temporarily discontinue treatment in patients that develop intestinal or stomal obstruction; teduglutide may be resumed (if clinically indicated) once the obstruction is resolved.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Teduglutide may increase the risk of hyperplastic changes, including neoplasia. In patients at increased risk for malignancy, consider treatment only if benefits outweigh the risks. Discontinue treatment in patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic); evaluate risk versus benefit in patients with active non-GI malignancy. Monitor for small bowel neoplasia; remove any benign neoplasm. Discontinue in patients who develop small bowel cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: Pancreatitis has been reported; monitor serum lipase and amylase ≤6 months prior to initiation of therapy and at least every 6 months for duration of therapy. If clinically meaningful changes are detected, evaluate for pancreatitis and reassess the need for continued teduglutide treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral medications: Teduglutide may increase absorption of oral medications; monitor for adverse effects of concomitant oral medications, particularly those with a narrow therapeutic index.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal function impairment: Use with caution; reduced doses required in moderate to severe renal impairment and end-stage renal disease (ESRD).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation: Treatment discontinuation may result in fluid and electrolyte imbalance. Carefully monitor fluid/electrolyte status.</p></div>
<div class="block foc drugH1Div" id="F16116960"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gattex: 5 mg</p></div>
<div class="block geq drugH1Div" id="F16136196"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570465"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Gattex Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2,094.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871545"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Revestive: 5 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F16136131"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> For SUBQ use only; do not administer IM or IV. Rotate injection site between thighs, upper arms, and 4 quadrants of the abdomen. Do not inject into areas where skin is bruised, red, hard, or tender. Following patient training and instructions on self-administration, adult patients may self-administer treatment.</p></div>
<div class="block admp drugH1Div" id="F53478003"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SubQ: For subcutaneous administration only; do not administer IM or IV. Rotate injection site between thighs, upper arms, and quadrants of the abdomen.</p></div>
<div class="block meg drugH1Div" id="F15878138"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F203441s018lbl.pdf%23page%3D17&amp;token=QFIFz%2FEAt0ZoTgaK%2Fix0JmV2r15ZSZPXec2C6ctwUCCSbNqnqTQVajJDnPokwNqcxkpWKZTPy4u1%2FuGF8xFy1sh9ArtS8EAqeDsB7BD4O6CAu3MBEEZqK145tRy9zOo4&amp;TOPIC_ID=87469" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203441s018lbl.pdf#page=17</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F15845564"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Short bowel syndrome, parenteral support dependent: </b>Treatment of short bowel syndrome in adults and pediatric patients ≥1 year of age who are dependent on parenteral support.</p></div>
<div class="block cyt drugH1Div" id="F16162330"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16162328"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Benzodiazepines: Teduglutide may increase the serum concentration of Benzodiazepines. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F16136001"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to use of teduglutide in pregnancy is limited.</p>
<p style="text-indent:0em;margin-top:2em;">Short bowel syndrome may cause maternal malnutrition, which is associated with adverse fetal effects, including congenital malformations, intrauterine growth restriction, low birth weight, perinatal mortality and preterm birth.</p></div>
<div class="block brc drugH1Div" id="F16136003"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if teduglutide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, including tumorigenicity, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F16136136"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">In all patients, serum bilirubin, alkaline phosphatase, lipase, and amylase (baseline [within 6 months prior to initiation] and every 6 months thereafter); monitor fluid status, especially in patients with cardiovascular disease; signs/symptoms of intestinal obstruction; signs/symptoms suggestive of gallbladder disease or pancreatitis; monitor fluid and electrolyte balance following therapy discontinuation. In adults, perform colonoscopy of entire colon with removal of polyps at baseline (within 6 months prior to initiation), 1 year, and ≤5 years thereafter if no polyps found, or more frequent if clinically necessary; follow current guidelines if polyps are found. In children/adolescents, test fecal occult blood at baseline (within 6 months prior to initiation) and yearly during treatment; perform colonoscopy/sigmoidoscopy if unexplained blood in stool at baseline and after 1 year of treatment, every 5 years thereafter during treatment, or if new or unexplained GI bleeding occurs.</p></div>
<div class="block pha drugH1Div" id="F16136098"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Teduglutide is an analog of glucagon-like peptide-2 (GLP-2), which is secreted in the distal intestine. Endogenous GLP-2 increases intestinal and portal blood flow while inhibiting gastric acid secretion, thereby reducing intestinal losses and improving intestinal absorption. Teduglutide binds and activates GLP-2 receptors, resulting in release of mediators including insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF).</p></div>
<div class="block phk drugH1Div" id="F16136100"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 0.1 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Similar to endogenous catabolism of GLP-2 but slower due to a single amino acid substitution (Ferrone 2006)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: 88%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 11 years: 0.7 ± 0.2 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Children 12 to 17 years: 1 ± 0.01 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1.3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SubQ: 3 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="block phksp drugH1Div" id="F51221498"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Teduglutide exposure is increased in patients with moderate or severe renal impairment or ESRD.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Teduglutide exposure is decreased in patients with moderate hepatic impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059519"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gattex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Gattex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Revestive</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27855998">
<a name="27855998"></a>Carter BA, Cohran VC, Cole CR, et al. Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome. <i>J Pediatr</i>. 2017;181:102-111.e5. doi: 10.1016/j.jpeds.2016.10.027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teduglutide-drug-information/abstract-text/27855998/pubmed" id="27855998" target="_blank">27855998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16705029">
<a name="16705029"></a>Ferrone M, Scolapio JS. Teduglutide for the treatment of short bowel syndrome. <i>Ann Pharmacother</i>. 2006;40(6):1105-1109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teduglutide-drug-information/abstract-text/16705029/pubmed" id="16705029" target="_blank">16705029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gattex.1">
<a name="Gattex.1"></a>Gattex (teduglutide) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21317170">
<a name="21317170"></a>Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. <i>Gut</i>. 2011;60(7):902-914.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teduglutide-drug-information/abstract-text/21317170/pubmed" id="21317170" target="_blank">21317170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22982184">
<a name="22982184"></a>Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. <i>Gastroenterology</i>. 2012;143(6):1473-1481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/teduglutide-drug-information/abstract-text/22982184/pubmed" id="22982184" target="_blank">22982184</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Revestive (teduglutide) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; December 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 87469 Version 131.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
